Business Context and Reporting Period
Company: Humana Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Humana operates two primary segments: Insurance (Medicare Advantage, Medicaid, and specialty benefits) and CenterWell (pharmacy, primary care, and home solutions). As of December 31, 2025, the company served approximately 15 million medical benefit plan members and 4.7 million specialty product members. Approximately 83% of total premiums and services revenue was derived from federal government contracts.
Key Financial Metrics
| Metric (in millions, except per share) | 2025 | 2024 |
|---|---|---|
| Total Revenues | $129,664 | $117,761 |
| Net Income Attributable to Humana | $1,188 | $1,207 |
| Diluted Earnings Per Share | $9.84 | $9.98 |
| Operating Cash Flow | $921 | $2,966 |
| Cash and Cash Equivalents (Year End) | $4,200 | $2,221 |
| Total Debt (Long-term + Short-term) | $12,369 | $11,721 |
| Benefit Ratio | 90.2% | 89.8% |
| Operating Cost Ratio | 12.0% | 11.8% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 10.1% to $129.7 billion, driven by a 9.6% increase in premiums revenue ($122.8 billion) and a 31.6% increase in services revenue ($5.8 billion). Premium growth was fueled by higher per-member Medicare premiums (due to Inflation Reduction Act subsidies) and growth in state-based contracts and stand-alone PDPs.
- Profitability: Net income decreased slightly by 1.6% to $1.188 billion. This decline was significantly impacted by non-recurring items, including a $67 million loss on the sale of a business, $449 million in value creation initiative charges, and $253 million in impairment charges.
- Membership Shifts: Individual Medicare Advantage membership declined 7.3% (412,500 members) due to strategic exits from unprofitable plans. Conversely, Medicare stand-alone PDP membership grew 7.6%, and state-based contracts grew 10.7%.
- Cash Flow: Operating cash flow decreased significantly by $2.0 billion to $0.9 billion, primarily due to timing impacts on receivables related to the Inflation Reduction Act and unfavorable working capital changes.
- Strategic Exits: The company finalized its exit from the Employer Group Commercial Medical Products business during 2025.
Guidance, Outlook, and Risks
- 2026 Membership Outlook: Management anticipates net membership growth in Individual Medicare Advantage of approximately 25%, Group Medicare Advantage of 150,000 members, and Medicare stand-alone PDP of 1 million members.
- Regulatory Litigation (RADV): Humana is engaged in significant litigation regarding the CMS Risk-Adjustment Data Validation (RADV) rule. While a district court vacated the rule in September 2025, the government has appealed. The outcome remains uncertain and could materially impact future revenues if the rule is reinstated without the "FFS Adjuster."
- Star Ratings: The number of Medicare Advantage plans rated 4-star or higher declined significantly in 2025. Humana has filed a lawsuit to vacate the 2025 Star Ratings. A failure to prevail could negatively impact 2026 quality bonus payments and revenues.
- Value Creation Initiatives: The company is executing a multi-year transformation program to re-align its cost structure. Charges of $449 million were recorded in 2025, with additional charges expected in future periods.
- Cybersecurity: The company faces ongoing risks from cybersecurity attacks, noting a significant incident at a third-party provider (Change Healthcare) in 2024. While no material impact was recorded through 2025, future attacks could disrupt operations.
Investor Verification Checklist
- Star Rating Impact: Verify the status of the lawsuit challenging the 2025 Star Ratings and the potential financial impact on 2026 quality bonuses if the ratings stand.
- RADV Litigation Outcome: Monitor the appeal of the RADV rule vacatur; a reversal could trigger significant premium recoveries.
- Membership Mix: Confirm the sustainability of growth in State-based contracts and PDPs to offset the strategic decline in Individual Medicare Advantage.
- Value Creation Costs: Track the execution of the transformation program and the magnitude of future charges versus realized cost savings.
- Working Capital: Assess the normalization of receivables and operating cash flows following the timing impacts of the Inflation Reduction Act in 2025.